Management of hepatocellular carcinoma prior to liver transplantation: latest developments
Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts tra...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis
2025-12-01
|
| Series: | Hepatic Oncology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20450923.2025.2549676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227282670944256 |
|---|---|
| author | Antoine Robert Thomas M. Hunold Neehar D. Parikh |
| author_facet | Antoine Robert Thomas M. Hunold Neehar D. Parikh |
| author_sort | Antoine Robert |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation. |
| format | Article |
| id | doaj-art-3dcba8eee1d34645b6ac6074c9b41779 |
| institution | Kabale University |
| issn | 2045-0923 2045-0931 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis |
| record_format | Article |
| series | Hepatic Oncology |
| spelling | doaj-art-3dcba8eee1d34645b6ac6074c9b417792025-08-23T13:09:52ZengTaylor & FrancisHepatic Oncology2045-09232045-09312025-12-0112110.1080/20450923.2025.2549676Management of hepatocellular carcinoma prior to liver transplantation: latest developmentsAntoine Robert0Thomas M. Hunold1Neehar D. Parikh2Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USADivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USADivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USAHepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation.https://www.tandfonline.com/doi/10.1080/20450923.2025.2549676Hepatocellular carcinomaliver transplantationdownstagemilantransarterial chemoembolizationtransarterial radioembolization |
| spellingShingle | Antoine Robert Thomas M. Hunold Neehar D. Parikh Management of hepatocellular carcinoma prior to liver transplantation: latest developments Hepatic Oncology Hepatocellular carcinoma liver transplantation downstage milan transarterial chemoembolization transarterial radioembolization |
| title | Management of hepatocellular carcinoma prior to liver transplantation: latest developments |
| title_full | Management of hepatocellular carcinoma prior to liver transplantation: latest developments |
| title_fullStr | Management of hepatocellular carcinoma prior to liver transplantation: latest developments |
| title_full_unstemmed | Management of hepatocellular carcinoma prior to liver transplantation: latest developments |
| title_short | Management of hepatocellular carcinoma prior to liver transplantation: latest developments |
| title_sort | management of hepatocellular carcinoma prior to liver transplantation latest developments |
| topic | Hepatocellular carcinoma liver transplantation downstage milan transarterial chemoembolization transarterial radioembolization |
| url | https://www.tandfonline.com/doi/10.1080/20450923.2025.2549676 |
| work_keys_str_mv | AT antoinerobert managementofhepatocellularcarcinomapriortolivertransplantationlatestdevelopments AT thomasmhunold managementofhepatocellularcarcinomapriortolivertransplantationlatestdevelopments AT neehardparikh managementofhepatocellularcarcinomapriortolivertransplantationlatestdevelopments |